{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:54:01Z","timestamp":1785772441833,"version":"3.56.0"},"reference-count":74,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T00:00:00Z","timestamp":1327017600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:p>Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes. Prevention of menorrhagia, defined as heavy regular menstrual cycles with more than 80 ml of blood loss\/cycle or a cycle duration longer than 7 days, in this patient population is the goal of therapy. Gonadotropin\u2010releasing hormone analogs (e.g., leuprolide) are promising therapies that have been shown to decrease vaginal bleeding during periods of thrombocytopenia and to have minimal adverse effects other than those associated with gonadal inhibition. In patients who experience menorrhagia despite preventive therapies, or in patients who have thrombocytopenia and menorrhagia at diagnosis, treatment is indicated. For these women, treatment options may include platelet transfusions, antifibrinolytic therapy (e.g., tranexamic acid), continuous high\u2010dose oral contraceptives, cyclic progestins, or other therapies for more refractory patients such as danazol, desmopressin, and recombinant factor VIIa. Hormonal therapies are often the mainstay of therapy in women with menorrhagia secondary to thrombocytopenia, but data for these agents are sparse. The most robust data for the treatment of menorrhagia are for tranexamic acid. Most women receiving tranexamic acid in randomized trials experienced meaningful reductions in menstrual bleeding, and this translated into improved quality of life; however, these trials were not performed in patients with cancer. Further clinical trials are warranted to evaluate both preventive and therapeutic agents for menorrhagia in premenopausal women with cancer who are receiving myelosuppressive chemotherapy.<\/jats:p>","DOI":"10.1592\/phco.31.11.1092","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T09:55:21Z","timestamp":1319536521000},"page":"1092-1110","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Management of Menorrhagia Associated with Chemotherapy\u2010Induced Thrombocytopenia in Women with Hematologic Malignancy"],"prefix":"10.1002","volume":"31","author":[{"given":"Jill S.","family":"Bates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Buie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Brock","family":"Woodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2008.03.001"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3929"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01586.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmm001"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.111795"},{"key":"e_1_2_1_7_2","first-page":"704","article-title":"Guidelines for the management of abnormal uterine bleeding","volume":"23","author":"Vilos GA","year":"2001","journal-title":"J Obstet Gynaecol Can"},{"key":"e_1_2_1_8_2","first-page":"58","article-title":"Approach to diagnosis and management of abnormal uterine bleeding","volume":"53","author":"Telner DE","year":"2007","journal-title":"Can Fam Physician"},{"key":"e_1_2_1_9_2","first-page":"1915","article-title":"Abnormal uterine bleeding","volume":"69","author":"Albers JR","year":"2004","journal-title":"Am Fam Physician"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.19.6.590"},{"key":"e_1_2_1_11_2","first-page":"1813","article-title":"Treatment of menorrhagia","volume":"75","author":"Apgar BS","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/8.1.60"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.07.1315"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.10.060"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0b013e3181932a37"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920009788897966"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0023"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K09E-185"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427020-00001"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.07.016"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.532200"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.526098"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.813"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03720140043031"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1718"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093726"},{"key":"e_1_2_1_27_2","volume-title":"Lysteda (tranexamic acid) package insert","author":"Ferring Pharmaceuticals, Inc.","year":"2010"},{"key":"e_1_2_1_28_2","volume-title":"Mirena (levonorgestrel\u2010releasing intrauterine system) package insert","author":"Bayer HealthCare Pharmaceuticals, Inc.","year":"2009"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0b013e3181706620"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704577"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000279138.64895.2b"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199603)51:3<248::AID-AJH17>3.0.CO;2-C"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097723"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701187"},{"key":"e_1_2_1_35_2","first-page":"537","article-title":"Inducing amenorrhea during bone marrow transplantation: a pilot study of leuprolide acetate","volume":"42","author":"Laufer MR","year":"1997","journal-title":"J Reprod Med"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22199"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420404"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241070-00003"},{"key":"e_1_2_1_39_2","unstructured":"SweetmanS ed.Martindale: the complete drug reference. Thomson Reuters. Available fromhttp:www.thomsonhc.comhomedispatch. Accessed February 21 2011."},{"key":"e_1_2_1_40_2","volume-title":"Lupron (leuprolide acetate) package insert","author":"Abbott","year":"2010"},{"key":"e_1_2_1_41_2","volume-title":"Eligard (leuprolide acetate) package insert","author":"Tolmar, Inc.","year":"2010"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/03000605900180S114"},{"key":"e_1_2_1_43_2","first-page":"3","article-title":"Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study","volume":"14","author":"Gerhard I","year":"1992","journal-title":"Clin Ther"},{"key":"e_1_2_1_44_2","first-page":"179","article-title":"Long\u2010term personalized GnRH agonist therapy without estrogen supplementation for recurrent endometriotic catamenial pneumothorax: case report","volume":"34","author":"Tanaka T","year":"2007","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1028-4559(09)60209-6"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.10.020"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1320699"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1159\/000066445"},{"issue":"779","key":"e_1_2_1_49_2","first-page":"e6","article-title":"Noninfective cutaneous granuloma with leuprorelin acetate\u2014reality of myth","volume":"69","author":"Dangle P","year":"2007","journal-title":"Urology"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2009.01270.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(03)00141-0"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmi019"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.01.061"},{"key":"e_1_2_1_54_2","first-page":"1371","article-title":"Abnormal uterine bleeding","volume":"60","author":"Oriel K","year":"1999","journal-title":"Am Fam Physician"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jama.1966.03110220103034","article-title":"The effect of oral contraceptives on the liver","volume":"198","author":"Schaffner F","year":"1966","journal-title":"JAMA"},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Norethisterone treatment, a major risk factor for veno\u2010occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"Hagglund H","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020282"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04050.x"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.03.003"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f20177"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.01926.x"},{"key":"e_1_2_1_62_2","article-title":"Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding [published online ahead of print January 18, 2011]","author":"Moore KA","year":"2011","journal-title":"Am J Ther"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.508071"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001016.pub2"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2921"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1980.tb04489.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1989.tb03325.x"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(93)90269-O"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200111000-00007"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(90)90055-6"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(97)00163-1"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.08.017"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01156.x"},{"key":"e_1_2_1_74_2","article-title":"Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia [published online ahead of print May 11, 2010]","author":"Balci YI","year":"2010","journal-title":"Clin Appl Throb Hemost"},{"key":"e_1_2_1_75_2","volume-title":"Treatment of menorrhagia in women with thrombocytopenia: comparison of platelet transfusion alone to platelet transfusion with continuous oral contraceptive pills","author":"Eunice Kennedy Shriver National Institute of Child Health and Human Development."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.11.1092","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.11.1092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:15:58Z","timestamp":1761045358000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.11.1092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1592\/phco.31.11.1092"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.11.1092","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"2012-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}